中华临床医师杂志（电子版）
中華臨床醫師雜誌（電子版）
중화림상의사잡지（전자판）
CHINESE JOURNAL OF CLINICIANS(ELECTRONIC VERSION)
2013年
12期
5382-5386
,共5页
杜平%申发娟%丛宁宁%康春生%王涛%张庆瑜
杜平%申髮娟%叢寧寧%康春生%王濤%張慶瑜
두평%신발연%총저저%강춘생%왕도%장경유
胃肿瘤%紫杉醇%细胞增殖%微RNA-200a%侵袭
胃腫瘤%紫杉醇%細胞增殖%微RNA-200a%侵襲
위종류%자삼순%세포증식%미RNA-200a%침습
Gastric neoplasms%Paclitaxel%Cell proliferation%miR-200a%Invasion
目的观察紫杉醇联合应用 miR-200 a 对胃癌 SGC-7901细胞增殖侵袭能力的影响。方法体外应用50 nmol/L紫杉醇单独处理胃癌SGC-7901细胞或联合应用脂质体转染miR-200 a模拟物（miR-200a mimics），通过流式细胞仪检测细胞凋亡水平和周期分布，克隆形成试验观察细胞的增殖能力，Tr-answell实验和细胞划痕试验观察细胞的侵袭迁移能力。通过以上实验比较单独应用紫杉醇与联合应用miR-200 a对胃癌细胞增值侵袭能力影响的差异，并探讨可能的作用机制。结果流式细胞凋亡检测表明50 nmol/L紫杉醇联合应用 miR-200a 细胞早期凋亡率高于单独用药组[（22.79±0.43）％ vs．（11.76±0.64）％，P＜0.05]，联合组阻滞于G2/M期细胞比例（63.74±1.76）％高于单独应用紫杉醇组的（51.75±2.01）％，结果具有统计学差异（ P＜0.01）；细胞克隆形成实验显示联合用药组克隆形成率与紫杉醇组相比[（4.03±0.25）％vs．（7.80±0.30）％]显著降低（P＜0.01）；Transwell侵袭实验表明联合用药组穿过小室的细胞数目少于紫杉醇组（22.00±2.00 vs．56.33±5.13，P＜0.01）；细胞划痕试验表明在划痕后48 h，联合组细胞迁移水平与单独用药组迁移率已有显著降低[21.43±2.34）％ vs．（54.26±2.49）％， P ＜0.01]。结论紫杉醇联合应用miR-200 a能增加紫杉醇对胃癌SGC-7901细胞增殖侵袭能力的抑制作用，为今后胃癌的化疗及基因靶向治疗提供新的思路。
目的觀察紫杉醇聯閤應用 miR-200 a 對胃癌 SGC-7901細胞增殖侵襲能力的影響。方法體外應用50 nmol/L紫杉醇單獨處理胃癌SGC-7901細胞或聯閤應用脂質體轉染miR-200 a模擬物（miR-200a mimics），通過流式細胞儀檢測細胞凋亡水平和週期分佈，剋隆形成試驗觀察細胞的增殖能力，Tr-answell實驗和細胞劃痕試驗觀察細胞的侵襲遷移能力。通過以上實驗比較單獨應用紫杉醇與聯閤應用miR-200 a對胃癌細胞增值侵襲能力影響的差異，併探討可能的作用機製。結果流式細胞凋亡檢測錶明50 nmol/L紫杉醇聯閤應用 miR-200a 細胞早期凋亡率高于單獨用藥組[（22.79±0.43）％ vs．（11.76±0.64）％，P＜0.05]，聯閤組阻滯于G2/M期細胞比例（63.74±1.76）％高于單獨應用紫杉醇組的（51.75±2.01）％，結果具有統計學差異（ P＜0.01）；細胞剋隆形成實驗顯示聯閤用藥組剋隆形成率與紫杉醇組相比[（4.03±0.25）％vs．（7.80±0.30）％]顯著降低（P＜0.01）；Transwell侵襲實驗錶明聯閤用藥組穿過小室的細胞數目少于紫杉醇組（22.00±2.00 vs．56.33±5.13，P＜0.01）；細胞劃痕試驗錶明在劃痕後48 h，聯閤組細胞遷移水平與單獨用藥組遷移率已有顯著降低[21.43±2.34）％ vs．（54.26±2.49）％， P ＜0.01]。結論紫杉醇聯閤應用miR-200 a能增加紫杉醇對胃癌SGC-7901細胞增殖侵襲能力的抑製作用，為今後胃癌的化療及基因靶嚮治療提供新的思路。
목적관찰자삼순연합응용 miR-200 a 대위암 SGC-7901세포증식침습능력적영향。방법체외응용50 nmol/L자삼순단독처리위암SGC-7901세포혹연합응용지질체전염miR-200 a모의물（miR-200a mimics），통과류식세포의검측세포조망수평화주기분포，극륭형성시험관찰세포적증식능력，Tr-answell실험화세포화흔시험관찰세포적침습천이능력。통과이상실험비교단독응용자삼순여연합응용miR-200 a대위암세포증치침습능력영향적차이，병탐토가능적작용궤제。결과류식세포조망검측표명50 nmol/L자삼순연합응용 miR-200a 세포조기조망솔고우단독용약조[（22.79±0.43）％ vs．（11.76±0.64）％，P＜0.05]，연합조조체우G2/M기세포비례（63.74±1.76）％고우단독응용자삼순조적（51.75±2.01）％，결과구유통계학차이（ P＜0.01）；세포극륭형성실험현시연합용약조극륭형성솔여자삼순조상비[（4.03±0.25）％vs．（7.80±0.30）％]현저강저（P＜0.01）；Transwell침습실험표명연합용약조천과소실적세포수목소우자삼순조（22.00±2.00 vs．56.33±5.13，P＜0.01）；세포화흔시험표명재화흔후48 h，연합조세포천이수평여단독용약조천이솔이유현저강저[21.43±2.34）％ vs．（54.26±2.49）％， P ＜0.01]。결론자삼순연합응용miR-200 a능증가자삼순대위암SGC-7901세포증식침습능력적억제작용，위금후위암적화료급기인파향치료제공신적사로。
Objective To observe the effect of paclitaxel combined with miR-200a mimics on proliferation and invasion of gastric cancer cell line SGC-7901 in vitro.Methods Human gastric cancer SGC-7901 cells were treated with 50 nmol/L paclitaxel alone or combined with transfecting miR-200a mimics.The proliferation capacity was detected by the cell cycle ,the percentage of apoptotic cells measured by flow cytometry and the cell cloning .The invasive ability of SGC-7901 cells was determined by Transwell assay and wound healing test .The different effect between using paclitaxel alone or combined with miR-200 a on proliferation and invasion of gastric cancer cell line SGC-7901 was contrasted through all the experiments above .The possible mechanism were also discussed . Results The experiments showed that the group treated both with paclitaxel and miR-200 a mimics had significantly higher cell apoptotic rate [ ( 22.79 ±0.43 )% vs.( 11.76 ±0.64 )%, P <0.05 ] and higher percentage of cells blocked at G2/M phase [ ( 63.74 ±1.76 )% vs.( 51.75 ±2.01 )%, P<0.01 ] , lower percentage of cell cloning [(4.03 ±0.25)%vs.(7.80 ±0.30)%,P<0.01],less trans-membrane cell number(22.00 ±2.00 vs.56.33 ± 5.13 ,P<0.01 ) , lower migrating rate after 48 h [ ( 21.43 ±2.34 )% vs.( 54.26 ±2.49 )%, P<0.01 ] than the group treated with paclitaxel alone .Conclusion Paclitaxel combined with miR-200a mimics has a better effect on inhibiting proliferation and invasion of human gastric cell line SGC-7901 than the paclitaxel ,which may provide a new way of gastric cancer chemotherapy and a potential gene therapertic target .
